金花清感颗粒治疗新型冠状病毒肺炎（COVID-19）的疗效和安全性：一项系统评价与Meta分析方案
Efficacy and safety of Jinhua Qinggan granules for coronavirus disease 2019 (COVID-19): A protocol of a systematic review and meta-analysis.
作者信息
Chen Hao, Song Yan-Ping, Gao Kai, Zhao Lin-Tao, Ma Li
机构信息
Pharmacy College, Shaanxi University of Chinese Medicine, Xianyang.
Shaanxi Academy of Traditional Chinese Medicine, Xi'an, Shaanxi, China.
出版信息
Medicine (Baltimore). 2020 Jun 12;99(24):e20612. doi: 10.1097/MD.0000000000020612.
BACKGROUND
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome (SARS)-COV2 and represents the causative agent of a potentially fatal disease. Jinhua Qinggan granules has definite effect in treating COVID-19 patients, but it has not been systematically evaluated for efficacy and safety.
METHODS
Retrieved the database, including the China National Knowledge Infrastructure (CNKI), Chinese Biomedical literature Database (CBM), Chinese Scientific and Journal Database (VIP), Wan Fang database, PubMed, and EMBASE. Evaluate methodological quality and judge risk of bias through the Cochrane manual. RevMan 5.3 and STATA 16.0 software were used to perform the meta-analysis.
RESULTS
This study will provide high-quality evidence of Jinhua Qinggan granules for COVID-19.
CONCLUSION
The conclusion of this study will provide evidence to determine whether Jinhua Qinggan granules is an effective treatment for COVID-19.
PROSPERO REGISTRATION NUMBER
CRD42020182373.
背景
2019冠状病毒病（COVID-19）由严重急性呼吸综合征（SARS）-COV2引起，是一种可能致命疾病的病原体。金花清感颗粒对治疗COVID-19患者有确切疗效，但尚未对其疗效和安全性进行系统评估。
方法
检索数据库，包括中国知网（CNKI）、中国生物医学文献数据库（CBM）、维普中文科技期刊数据库（VIP）、万方数据库、PubMed和EMBASE。通过Cochrane手册评估方法学质量并判断偏倚风险。使用RevMan 5.3和STATA 16.0软件进行荟萃分析。
结果
本研究将为金花清感颗粒治疗COVID-19提供高质量证据。
结论
本研究结论将为确定金花清感颗粒是否为COVID-19的有效治疗方法提供证据。
国际前瞻性注册系统（PROSPERO）注册号：CRD42020182373。
Zotero 插件